Compare SHEN & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHEN | LBRX |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United States |
| Employees | 1041 | 27 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 880.2M | 850.5M |
| IPO Year | 1994 | N/A |
| Metric | SHEN | LBRX |
|---|---|---|
| Price | $16.25 | $28.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $26.00 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 341.9K | 132.5K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $357,854,000.00 | N/A |
| Revenue This Year | $7.12 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.08 | N/A |
| 52 Week Low | $9.67 | $13.40 |
| 52 Week High | $17.35 | $33.47 |
| Indicator | SHEN | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.69 | 41.83 |
| Support Level | $12.85 | $22.39 |
| Resistance Level | $17.13 | $33.47 |
| Average True Range (ATR) | 0.67 | 1.60 |
| MACD | -0.03 | -0.75 |
| Stochastic Oscillator | 51.64 | 18.65 |
Shenandoah Telecommunications Co with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.